The FDA Just Sent 2,200 Companies a Very Uncomfortable Reminder

To put that in context: almost a third of the trials that should be feeding the public evidence base are just... silent. It's like discovering that 30% of students turned in blank exams, and nobody noticed for years.

Historically, the numbers have been even worse. A 2020 study found only 41% of completed trials reported results within the required one-year window. And a 2015 analysis of over 13,000 trials? A dismal 13.4% hit the deadline. Things have improved since then (twelve-month reporting rates climbed from 8.3% to 23.2% in a January 2025 analysis), but "better than terrible" still isn't good.

Who's Flunking, and Who's Passing?

Not all sponsors are created equal here. Industry sponsors report at the highest rate among the groups tracked. Academic sponsors? A rough 25.5%.

That gap makes intuitive sense. Big pharma companies have entire regulatory affairs departments, compliance teams, and legal counsel reminding them what's due. A university researcher juggling grant applications, teaching, and lab work might not even know the reporting requirement exists. But ignorance isn't a defense when the inspector comes knocking.

The Transparency Problem That Keeps Investors Up at Night

This isn't just a bureaucratic headache. It's a transparency crisis with real financial stakes.

FDA Commissioner Marty Makary didn't mince words, stating that "companies are suppressing unfavourable clinical trial results and keeping them secret from patients and the scientific community." When negative trial results vanish into the ether, the public record gets skewed toward success stories. Scientists designing the next trial don't learn from past failures. Doctors make treatment decisions based on incomplete evidence. And investors, critically, can't accurately price risk.

Consider a biotech stock trading at a premium because its lead compound looks promising based on published data. If a failed trial for a related indication was never reported, the market is essentially flying blind. Makary emphasized that sponsors have an "ethical obligation" to report results "regardless of the data's influence on the company's share price."

This push fits into a broader "radical transparency" campaign at the FDA. In 2025, the agency started publicly releasing complete response letters (the formal rejection notices it sends to companies whose drug applications don't pass muster). Forcing trial results into the open is the logical next step.

What Happens Next

Right now, the FDA is asking nicely. The letters are labeled as reminders, and the agency is encouraging voluntary compliance before escalating. Legal experts are already advising companies to audit their trial portfolios and submit any overdue results immediately.

But "asking nicely" comes with an implied threat. The enforcement toolkit includes Pre-Notices of Noncompliance (private warnings with a 30-day correction window), formal Notices of Noncompliance (public and permanent), and those daily fines that, at $10,000 a pop, add up fast. For a single trial sitting unreported for a year, that's potentially millions of dollars.

The timing matters too. The AACR Annual Meeting kicks off April 17 in San Diego, where oncology data (including a wave of antibody-drug conjugate presentations) will dominate headlines. Companies showing up with shiny new trial results while sitting on unreported old ones might find themselves in an awkward spotlight.

The Bottom Line

For almost 20 years, mandatory trial reporting has been one of those rules everyone knew about and few took seriously. The FDA's March 2026 outreach signals that the era of gentle nudges is winding down. Whether the agency actually follows through with fines remains the billion-dollar question; history suggests caution. But the reputational risk alone (a permanent noncompliance flag on ClinicalTrials.gov) may be enough to change behavior.

The 2,200 sponsors who just got a letter have a simple choice: upload the data, or wait for the next message, which won't be nearly as friendly.